Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.

Inclusion Criteria:

• Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks.
• Body Mass Index (BMI) of approximately 18 to 40 kg/m2 inclusive.
• Total body weight >50 kg (110 lbs).
• Male or female subjects between the ages of 18 and 85 years.

Exclusion Criteria:

• Subjects with acute renal disease and/or history of renal transplant.
• Supine BP at Screening ≥160 mm Hg systolic or ≥95 mm Hg diastolic.
• Supine BP at Screening ≤80 mm Hg systolic or ≤40 mm Hg diastolic.